左心耳封堵在非瓣膜性心房颤动卒中的预防作用

doi:10.3969/j.issn.1004-583X.2016.01.003

临床荟萃 ›› 2016, Vol. 31 ›› Issue (1): 10-13.doi: 10.3969/j.issn.1004-583X.2016.01.003

左心耳封堵在非瓣膜性心房颤动卒中的预防作用

齐淑媛, 田颖

首都医科大学附属北京朝阳医院心脏中心/心律失常科,北京 100020

收稿日期:2015-10-14 出版日期:2016-01-05 发布日期:2016-04-19
通讯作者: 田颖,Email:doctorty2000@163.com
作者简介:田颖,医学博士后,副主任医师,首都医科大学附属北京朝阳医院房颤中心副主任。兼任:中国医师协会心律专业委员会青年委员会,副主任委员; 中华医学会心电生理和起搏分会青年委员会,委员;中国生物医学工程学会心律学会青年委员会,委员;北京医学会心电生理与起搏分会青年委员会,副主任委员;中华医学会心电生理和起搏分会第六届委员会电生理女医师联盟,委员;中国医师协会心律专业委员会女医师专业委员会,委员;北京心律失常联盟(AA联盟),委员。
基金资助:
国家自然科学基金资助项目(81470023,81100125,81307293)

Role of percutaneous left atrial appendage occlusion in stroke prevention for nonvalvular atrial fibrillation

Qi Shuyuan,Tian Ying

Center for Arrhythmia, Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

Received:2015-10-14 Online:2016-01-05 Published:2016-04-19
Contact: Tian Ying, Email: doctorty2000@163.com

摘要/Abstract

摘要： 血栓栓塞事件是心房颤动(房颤)最严重的并发症,及早识别并预防其栓塞风险至关重要。传统的抗凝治疗在预防非瓣膜性房颤患者的血栓栓塞事件方面存在一定局限性。左心耳部被证实为房颤患者血栓形成的主要部位,这一发现促使了经皮左心耳封堵技术的迅速发展。与抗凝药物相比,经皮左心耳封堵术可有效降低房颤患者血栓栓塞事件的发生率,且适用于抗凝禁忌的房颤患者。目前,WATCHMAN与ACP封堵装置已被授权进入欧盟市场,LARIAT左心耳结扎装置也因其有效性及安全性被美国FDA批准应用。经皮左心耳封堵及结扎术的适应证广,安全性高,有望成为多数房颤患者预防血栓栓塞事件的选择。

关键词: 心房颤动, 血栓栓塞, 左心耳封堵

Abstract: Thromboembolism is the most serious complication in patients with atrial fibrillation(AF).It is crucial to predict and reduce the thromboembolic risk as soon as possible.Chronic anticoagulaion therapy has certain limitations in the prevention of thromboembolic events.Left atrial appendage(LAA) was confirmed as the main part of thrombus formation in patients with nonvalvular AF.As a result,percutaneous LAA occlusion has been advocated as a strategy for the prevention of thromboembolic event.LAA occlusion can effectively reduce the incidence of thromboembolic events in patients with nonvalvular AF and was also considered for patients with contraindications to oral anticoagulation.The WATCHMAN and ACP device have been authorized to enter the European Union market.LARIAT ligation device was also approved by US Food and Drug Administration because of its efficacy and safety.Due to its wide indications and high safety,percutaneous LAA occlusion or suture ligation is expected to become a reasonable alternative to prevent thromboembolic events for most patients with AF.

Key words: atrial fibrillation, thromboembolism, percutaneous left atrial appendage transcatheter occlusion

中图分类号:

R541.75

齐淑媛, 田颖. 左心耳封堵在非瓣膜性心房颤动卒中的预防作用[J]. 临床荟萃, 2016, 31(1): 10-13.

Qi Shuyuan,Tian Ying. Role of percutaneous left atrial appendage occlusion in stroke prevention for nonvalvular atrial fibrillation[J]. Clinical Focus, 2016, 31(1): 10-13.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.01.003

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I1/10

参考文献

[1] Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study[J]. Circulation, 2004,110(9):1042-1046.
[2] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study[J]. Stroke, 1991,22(8):983-988.
[3] Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study[J]. Stroke, 1996,27(10):1760-1764.
[4] Garcia DA, Hylek E. Reducing the risk for stroke in patients who have atrial fibrillation[J]. Cardiol Clin, 2008,26(2):267-275.
[5] 徐荣,郭金城,郭明.老年心房颤动患者华法林长期抗凝治疗的效果与安全性[J].临床荟萃,2015,30(3):272-275.
[6] 王全河,杨国杰,吴楠.老年非瓣膜病性心房颤动患者华法林钠抗凝疗效及安全性研究[J].临床荟萃,2009,24 (5):399-401.
[7] Blackshear JL,Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation[J]. Ann Thorac Surg, 1996,61(2):755-759.
[8] Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience[J]. Circulation, 2002,105(16):1887-1889.
[9] Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials[J]. J Am Coll Cardiol, 2005,46(1):9-14.
[10] Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study[J]. JACC Cardiovasc Interv, 2009,2(7):594-600.
[11] Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation[J]. J Am Coll Cardiol, 2007,49(13):1490-1495.
[12] Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial[J]. Lancet, 2009,374(9689):534-542.
[13] Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry[J]. Circulation, 2011,123(4):417-424.
[14] Holmes DJ, Kar S, Price MJ, et al.Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial[J]. J Am Coll Cardio, 2014, 64(1):1-12.
[15] Holmes DJ, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis[J]. J Am Coll Cardio, 2015, 65(24):2614-2623.
[16] Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)[J]. J Am Coll Cardiol, 2013,61(25):2551-2556.
[17] Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience[J]. Catheter Cardiovasc Interv, 2011,77(5):700-706.
[18] Lam YY, Yip GW, Yu CM, et al. Left atrial appendage closure with AMPLATZER cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience[J]. Catheter Cardiovasc Interv, 2012,79(5):794-800.
[19] Danna P, Proietti R, Sagone A, et al. Does left atrial appendage closure with a cardiac plug system reduce the stroke risk in nonvalvular atrial fibrillation patients? A single-center case series[J]. Pacing Clin Electrophysiol, 2013,36(3):347-353.
[20] Lam YY, Yan BP, Doshi SK, et al. Preclinical evaluation of a new left atrial appendage occluder (Lifetech LAmbre device) in a canine model[J]. Int J Cardiol, 2013,168(4):3996-4001.
[21] Lee RJ, Bartus K, Yakubov SJ. Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA: initial experience in a canine model[J]. Circ Cardiovasc Interv, 2010,3(3):224-229.
[22] Bartus K, Bednarek J, Myc J, et al. Feasibility of closed-chest ligation of the left atrial appendage in humans[J]. Heart Rhythm, 2011,8(2):188-193.
[23] Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience[J]. J Am Coll Cardiol, 2013,62(2):108-118.
[24] Pillarisetti J, Reddy YM, Gunda S, et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type of leaks and their clinical implications[J]. Heart Rhythm,2015,12(7):1501-1507.
[25] Calvo N,Salterain N,Arguedas H,et al. Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation[J]. Europace, 2015,17(10):1533-1540.

左心耳封堵在非瓣膜性心房颤动卒中的预防作用

Role of percutaneous left atrial appendage occlusion in stroke prevention for nonvalvular atrial fibrillation

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王奕涵, 秦旭雁, 韩宣泽, 王樱洁, 高菲菲, 陈春红, 张岭楠, 张芳. 利伐沙班用于HASBLED评分≥3分的高龄非瓣膜性心房颤动患者的有效性和安全性[J]. 临床荟萃, 2024, 39(2): 121-124.
[2]	李雯琳, 张志. 心房颤动患者左心耳形态结构和功能与左心耳血栓及心源性卒中的关系研究进展[J]. 临床荟萃, 2024, 39(2): 168-171.
[3]	王震, 杨晓月, 李少杰, 王贤, 陈淑霞, 谷剑. 射血分数保留的心力衰竭合并心房颤动患者临床特征及再入院危险因素[J]. 临床荟萃, 2023, 38(4): 308-314.
[4]	冷婉铜, 陶洁. 多发性骨髓瘤患者治疗后发生静脉血栓栓塞的危险因素[J]. 临床荟萃, 2023, 38(4): 340-345.
[5]	张芳, 张伊超, 贾辛未, 李建龙, 陈春红. 心房颤动高CHA2DS2-VASc评分≥75岁住院患者随访1年结果分析[J]. 临床荟萃, 2023, 38(2): 117-120.
[6]	马静红, 杨倩, 贾永建, 党懿. 心房颤动导管消融围术期不间断新型口服抗凝剂和不间断华法林抗凝导致心脏压塞风险的荟萃分析[J]. 临床荟萃, 2022, 37(9): 773-778.
[7]	张海福, 叶向晴, 陈者旭, 陈施鉴, 杨栋, 张邢炜. 适量运动对心房颤动患者预后的影响:系统综述与Meta分析[J]. 临床荟萃, 2022, 37(6): 485-489.
[8]	章敬水, 徐亚男, 王钧, 杨毅, 姜海兵, 唐龙, 王贤平, 邵名亮. 新发的不同类型心力衰竭合并心房颤动的临床特点和远期预后分析[J]. 临床荟萃, 2022, 37(6): 504-509.
[9]	王娇燕, 章迎春, 任珂明, 马国峰, 应可净. 奥氮平使用合并静脉血栓栓塞症16例临床分析[J]. 临床荟萃, 2022, 37(12): 1108-1113.
[10]	李卫伟, 李亚男. 左房容积指数用于预测心房颤动患者射频消融后复发的meta分析[J]. 临床荟萃, 2022, 37(11): 965-968.
[11]	安景景, 王小娟, 邓爱云. 预激综合征伴心房颤动射频消融术后心房颤动复发率的meta分析[J]. 临床荟萃, 2022, 37(10): 899-904.
[12]	曹晶晶, 张英杰, 常丽娟. 心房颤动发病机制及相关生物标志物研究进展[J]. 临床荟萃, 2022, 37(10): 946-949.
[13]	沈瑞, 雷艳花, 贾昊鹍. 145例弥漫性大B细胞淋巴瘤患者静脉血栓栓塞发生率及危险因素分析[J]. 临床荟萃, 2022, 37(1): 43-45.
[14]	赵美丽, 肖立远, 刘林, 康超, 张秋香. NT-proBNP、hs-CRP、LAD与慢性心力衰竭合并心房颤动的相关性[J]. 临床荟萃, 2021, 36(5): 412-415.
[15]	狄鼎新, 张铮, 李叶桐, 邹古明, 高红梅, 李文歌. 合并恶性高血压和血栓性微血管病的青年IgA肾病患者治疗及预后[J]. 临床荟萃, 2021, 36(3): 256-261.